| 000 | 01543 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513210313.0 | ||
| 264 | 0 | _c20000712 | |
| 008 | 200007s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(00)00696-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBhatt, D L | |
| 245 | 0 | 0 |
_aThe benefit of abciximab in percutaneous coronary revascularization is not device-specific. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cMay 2000 |
||
| 300 |
_a1060-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAtherectomy, Coronary |
| 650 | 0 | 4 |
_aCoronary Disease _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aStents |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aLincoff, A M | |
| 700 | 1 | _aCaliff, R M | |
| 700 | 1 | _aSimoons, M L | |
| 700 | 1 | _aTcheng, J E | |
| 700 | 1 | _aBrener, S J | |
| 700 | 1 | _aWolski, K E | |
| 700 | 1 | _aTopol, E J | |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 85 _gno. 9 _gp. 1060-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(00)00696-2 _zAvailable from publisher's website |
| 999 |
_c10734702 _d10734702 |
||